Innate Immune Markers in Mothers and Fathers of Children Newly Diagnosed with Cancer

Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104-4399, USA.
NeuroImmunoModulation (Impact Factor: 1.88). 02/2008; 15(2):102-7. DOI: 10.1159/000148192
Source: PubMed


The diagnosis of a life-threatening illness in a child is one of the most stressful events imaginable for parents and is associated with increased anxiety and distress. Despite associations between stress and immune function in animal and human models, the immune function in caregivers of children at the time of a child-related potentially traumatic event, like cancer, is not known.
Nineteen parents (11 mothers, 8 fathers), representing six caregiver pairs, provided blood for natural killer (NK) cell count by flow cytometry and function assays [% NK whole blood, absolute NK whole blood, LU(20) (lytic unit) peripheral blood mononuclear cells, LU(20) NK cells] and completed self-report measures (acute stress) within 2 weeks of learning their child had cancer. The NK cell assay was also completed with a sample of healthy adults, the immune reference group.
There were similar levels of NK cell activity between caregivers and the immune reference group. Immune level and psychological outcomes were not associated. LU(20) peripheral blood mononuclear cells and LU(20) NK cells were each correlated at r = 0.83 between mothers and fathers in the same family.
Although based on a small sample, these preliminary results suggest that knowledge about stress responses in parents of children with life-threatening illness may be important and provide novel data regarding the shared impact of stress on immune function within caregiver dyads.

Download full-text


Available from: Steven Douglas, Sep 03, 2014
  • Source
    • "In addition to completing self-report questionnaires and accepting randomization to SCCIP-ND or TAU, participants were also asked to consent to providing 20 cc of blood at each data collection, related to a secondary aim of this study, examining neuroimmune markers in parents of children newly diagnosed with cancer (Lutz Stehl et al., 2008). Consenting to this part of the study was optional and did not affect participation in the primary study. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To report acceptability, feasibility, and outcome data from a randomized clinical trial (RCT) of a brief intervention for caregivers of children newly diagnosed with cancer. Eighty-one families were randomly assigned following collection of baseline data to Intervention or Treatment as Usual (TAU). Recruitment and retention rates and progression through the protocol were tracked. Measures of state anxiety and posttraumatic stress symptoms served as outcomes. Difficulties enrolling participants included a high percentage of newly diagnosed families failing to meet inclusion criteria (40%) and an unexpectedly low participation rate (23%). However, movement through the protocol was generally completed in a timely manner and those completing the intervention provided positive feedback. Outcome data showed no significant differences between the arms of the RCT. There are many challenges inherent in conducting a RCT shortly after cancer diagnosis. Consideration of alternative research designs and optimal timing for interventions are essential next steps.
    Full-text · Article · Sep 2009 · Journal of Pediatric Psychology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine the role of cortisol in posttraumatic stress symptomatology among mothers of children newly diagnosed with cancer. Mothers (N = 27) completed standardized measures of posttraumatic stress symptoms and provided salivary cortisol samples at the time of their child's cancer diagnosis and then monthly for 1 year. Random effects regression analyses of 351 person-by-time observations revealed that high levels of cortisol were associated with higher levels of posttraumatic stress symptoms (B = .12, p < .02). The mothers who exhibited higher cortisol levels at the time of their child's diagnosis showed statistically significant declines in symptomatology from diagnosis to 12 months postdiagnosis (B = .97, p < .0001) compared to mothers who exhibited lower cortisol levels at diagnosis (B = .003, p < .05). These findings offer some suggestions into possible neurobiological processes underlying posttraumatic stress symptoms and directions for future research and clinical intervention.
    Full-text · Article · Oct 2010 · Journal of Pediatric Psychology
  • [Show abstract] [Hide abstract]
    ABSTRACT: We previously developed a reliable and valid method for classifying the intensity of pediatric cancer treatment. The Intensity of Treatment Rating Scale (ITR-2.0) 1 classifies treatments into four operationally defined levels of intensity and is completed by pediatric oncology specialists based on diagnosis, stage, and treatment data from the medical record. Experience with the ITR-2.0 and recent changes in treatment protocols indicated the need for a minor revision and revalidation. Five criterion raters reviewed the prior items, independently proposing additions and/or changes in the classification of diseases/treatments. Subsequent to a group discussion of the proposed changes, a revised 43-item ITR was evaluated. Pediatric oncologists (n = 47) completed a two-part online questionnaire. Validity of the classifications was determined by the oncologists classifying each disease/treatment into one of the four levels of intensity. Inter-rater reliability was calculated by having each oncologist classify the treatments of 12 sample patients using the new version which we call the ITR-3. Agreement between median ratings of the 43 items for the pediatric oncologists and the criterion raters was high (r = 0.88). The median of the raters was either identical (81%) with the criterion ratings or discrepant by one level. Inter-rater reliability was very high when using the ITR-3 to classify 12 sample patients, with a median agreement of 0.90 and an intraclass correlation coefficient (r(ICC) = 0.86). With these minor modifications and updates, the ITR-3 remains a reliable and valid method for classifying pediatric oncology treatment protocols.
    No preview · Article · Jul 2012 · Pediatric Blood & Cancer